New Delhi, India -- (SBWire) -- 03/13/2018 --The Herpes Simplex Virus, also known as HSV, is an infection that causes Herpes which leads to small, painful, fluid-filled blisters on the skin, mouth, lips, eyes or genitals. This infection is categorized into two types: Herpes Simplex Virus Type-1 (HSV-1) and Herpes Simplex Virus Type-2 (HSV-2). HSV-1 is a highly contagious and common infection that is mainly transmitted by oral contact in or around the mouth, causing cold sores/Herpes Labialis as well as Genital Herpes in some cases. On the other hand, HSV-2 is transmitted sexually (genital-to-genital, oral-to-genital, or genital-to-oral) and perinatally (mother to child). Both HSV-1 and HSV-2 infections are lifelong.

According to the latest report of DelveInsight, "Herpes Simplex Virus (HSV) Infections-Market Insights, Epidemiology and Market Forecast-2027", the total prevalent cases of HSV in 7 major markets were around 228,552,199 in 2016. Out of these prevalent cases, type-specific prevalent cases of HSV infections were found out to be 186,990,090 in 2016, with a higher number of Herpes Labialis patients as compared to Genital Herpes patients. It has also been assessed that Herpes Labialis cases are expected to decrease and Genital Herpes cases are expected to increase in the upcoming years. Women are more likely to be seropositive for HSV infection than men and are also more likely to acquire the virus at an earlier age.

In 2017, WHO estimated that there are about 3.7 billion people under the age 50 (67%) with HSV-1 infection globally and an estimated 417 million people aged 15-49 (11%) worldwide were affected with HSV-2 infection. As per the Centers for Disease Control and Prevention, approximately 776,000 people in the United States develop new Herpes Infections, while one out of every six people aged 14 to 49 years has Genital herpes. The 7MM market size for HSV infections was found to be USD 2.2 Billion in 2016. The US has the highest share of the 2016 market for HSV infections followed by EU5 and Japan. As per DelveInsight's estimation, the global market size of HSV Infections is expected to grow at a significantly during 2016-2027.

The current HSV Infection market is mainly dependent on antiviral drugs and their generic versions. The market is flooded with already approved antiviral therapies such as Sitavig (Acyclovir), Denavir (penciclovir), Valtrex (valaciclovir), Famvir (famciclovir), Zovirax (Acyclovir sodium), Lipsovir (Acyclovir/hydrocortisone cream), and Abreva (docasanol 10%). Pritelivir and SQX770 are some of the upcoming therapies that are expected show takeover the herpes market. The report has covered detailed information about the pipeline drugs and upcoming therapies in the market. Epidemiology details covering 7MM and region-wise epidemiology information is provided to better understand the global distribution pattern of the indication.

Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the Herpes Simplex Virus market.
- To understand the future market competition in the Herpes Simplex Virus market and Insight reviews of the key market drivers and barriers.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:
- Avanir Pharmaceuticals
- Pfizer
- Novartis
- GlaxoSmithKline
- Medivir
- Genocea Biosciences
- AiCuris

Table of Contents:
1. Key Insights
2. Herpes Simplex Virus Market Overview at a Glance
2.1. Market Share (%) Distribution of Herpes Simplex Virus in 2016
2.2. Market Share (%) Distribution of Herpes Simplex Virus in 2027
3. Disease Background and Overview: Herpes Simplex Virus (HSV)
3.1. Introduction
3.2. Stages of Herpes infection
3.3. Clinical manifestations
3.4. Risk Factors
3.5. Disease Causes
3.6. HSV-Symptoms
3.7. Pathogenesis
3.8. HSV Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Disease Definition
4.3. Population and Forecast Parameters
4.4. 7MM Prevalent Population of Herpes Simplex Virus (HSV)
4.5. 7MM Type-Specific Prevalent Population of Herpes Simplex Virus (HSV)
4.6. Country Wise-Epidemiology of Herpes Simplex Virus (HSV)
4.6.1. United States
4.6.2. Prevalent Population of HSV in the United States
4.6.3. Type-Specific HSV Prevalence in the United States
4.6.4. Diagnosed Cases of HSV in the United States
4.6.5. Germany
4.6.6. Prevalent Population of HSV in Germany
4.6.7. Type-Specific HSV Prevalence in Germany
4.6.8. Diagnosed Cases of HSV in Germany
4.6.9. France
4.6.10. Prevalent Population of HSV in France
4.6.11. Type-Specific HSV Prevalence in France
4.6.12. Diagnosed Cases of HSV in France
4.6.13. Italy
4.6.14. Prevalent Population of HSV in Italy
4.6.15. Type Specific HSV prevalence in Italy
4.6.16. Diagnosed cases of HSV in Italy
4.6.17. Spain
4.6.18. Prevalent Population of HSV in Spain
4.6.19. Type Specific HSV prevalence in Spain
4.6.20. Diagnosed cases of HSV in Spain
4.6.21. United Kingdom
4.6.22. Prevalent cases of HSV in the UK
4.6.23. Type Specific HSV prevalence in the UK
4.6.24. Diagnosed cases of HSV in the UK
4.6.25. Japan
4.6.26. Prevalent cases of HSV in Japan
4.6.27. Type Specific HSV prevalence in Japan
4.6.28. Diagnosed cases of HSV in Japan
5. Treatment Algorithm
5.1. Centers for Disease Control and Prevention (CDC): Guidelines for the treatment of Genital Herpes
5.2.WHO Recommendations for Treatment of Genital Herpes Simplex Virus
5.3. 2017 European Guidelines for Management of Genital Herpes
6. Unmet needs
7. Marketed drugs
7.1. Abreva: GSK/Avanir Pharmaceuticals
7.1.1. Drug Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.2. Viroptic Ophthalmic Solution (trifluridine) 1%: Pfizer Inc.
7.2.1. Drug Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Famvir: Novartis
7.3.1. Drug Description
7.3.2. Other development activities
7.3.3. Regulatory Milestones
7.3.4. Advantages & Disadvantages
7.3.5. Safety and Efficacy
7.3.6. Product Profile
7.4. Valtrex: GlaxoSmithKline
7.4.1. Drug Description
7.4.2. Other development activities
7.4.3. Regulatory Milestones
7.4.4. Advantages & Disadvantages
7.4.5. Safety and Efficacy
7.4.6. Product Profile
7.5. Denavir: Mylan Pharmaceuticals
7.5.1. Drug Description
7.5.2. Regulatory Milestones
7.5.3. Advantages & Disadvantages
7.5.4. Safety and Efficacy
7.5.5. Product Profile
7.6. Foscavir: Clinigen Group Plc.
7.6.1. Drug Description
7.6.2. Regulatory Milestones
7.6.3. Advantages & Disadvantages
7.6.4. Safety and Efficacy
7.6.5. Product Profile
7.7. Sitavig/Sitavir: BioAlliance Pharma
7.7.1. Drug Description
7.7.2. Regulatory Milestones
7.7.3. Advantages & Disadvantages
7.7.4. Safety and Efficacy
7.7.5. Product Profile
7.8. Zovirax: GlaxoSmithKline
7.8.1. Drug Description
7.8.2. Regulatory Milestones
7.8.3. Advantages & Disadvantages
7.8.4. Safety and Efficacy
7.8.5. Product Profile
7.9. Lipsovir: Medivir
7.9.1. Drug Description
7.9.2. Regulatory Milestones
7.9.3. Advantages & Disadvantages
7.9.4. Safety and Efficacy
7.9.5. Product Profile
8. Emerging Therapies
8.1. Key Cross Competition
9. Phase II/III Drugs
9.1. SQX770: Squarex
9.1.1. Drug Description
9.1.2. Product Profile
9.1.3. Clinical Development
9.1.4. Clinical Trials Information
9.2. BTL TML HSV: Beech Tree Labs
9.2.1. Drug Description
9.2.2. Product Profile
9.2.3. Other Development Activities
9.2.4. Clinical Development
9.2.5. Clinical Trials Information
9.2.6. Safety and Efficacy
9.2.7. Advantages and Disadvantages
9.3. GEN 003: Genocea Biosciences
9.3.1. Drug Description
9.3.2. Product Profile
9.3.3. Other Development Activities
9.3.4. Clinical Development
9.3.5. Clinical Trials Information
9.3.6. Safety and Efficacy
9.3.7. Advantages and Disadvantages
9.4. Pritelivir: AiCuris
9.4.1. Drug Description
9.4.2. Product Profile
9.4.3. Regulatory Milestones
9.4.4. Clinical Development
9.4.5. Clinical Trials Information
9.4.6. Safety and Efficacy
9.4.7. Advantages and Disadvantages
9.5. VCL-HB01: Vical
9.5.1. Drug Description
9.5.2. Product Profile
9.5.3. Other Development Activities
9.5.4. Clinical Development
9.5.5. Clinical Trials Information
9.5.6. Safety and Efficacy
9.5.7. Advantages and Disadvantages
9.6. M5210B: Maruho
9.6.1. Drug Description
9.6.2. Product Profile
10. Herpes Simplex Virus (HSV) Infection: Market Analysis
10.1. Key Findings
11. Herpes Simplex Virus (HSV) Infections: Total Market Size in 7MM
11.1. Total Market Size of HSV Infection in 7MM
11.2. Market size of HSV Infection by Clinical Manifestations in 7MM
11.3. EmergingTherapy-based Market Size of HSV Infection in 7MM
12. Market Size of HSV by Country
12.1. United States Market Analysis
12.1.1. Market Size of HSV Infection in the US
12.1.2. Market size of HSV Infection by Clinical Manifestations in the US
12.1.3. Treatment Type & Therapy Based Market Size of HSV Infection
12.1.4. Herpes Simplex Virus Infections Market by Emerging Therapies
12.2. Herpes Simplex Virus: EU5 Market Outlook
12.2.1. Germany
12.2.1.1. Market Size of HSV Infection in Germany
12.2.1.2. Market size of HSV Infection by Clinical Manifestations in Germany
12.2.1.3. Treatment Type & Therapy Based Market Size of HSV
12.2.1.4. Herpes Simplex Virus Infections Market by Emerging Therapies
12.2.2. France
12.2.2.1. Market Size of HSV Infection in France
12.2.2.2. Market size of HSV by Clinical Manifestations in France
12.2.2.3. Treatment Type & Therapy Based Market Size of HSV Infection
12.2.2.4. Herpes Simplex Virus Infections Market by Emerging Therapies
12.2.3. Italy
12.2.3.1. Market Size of HSV Infection in Italy
12.2.3.2. Market size of HSV Infection by Clinical Manifestations in Italy
12.2.3.3. Treatment Type & Therapy Based Market Size of HSV Infection
12.2.3.4. Herpes Simplex Virus Infections Market by Emerging Therapies
12.2.4. Spain
12.2.4.1. Market Size of HSV Infection in Spain
12.2.4.2. Market size of HSV Infection by Clinical Manifestations in Spain
12.2.4.3. Treatment Type & Therapy Based Market Size of HSV Infection
12.2.4.4. Herpes Simplex Virus Infections Market by Emerging Therapies
12.2.5. United Kingdom
12.2.5.1. Market Size of HSV Infection in the UK
12.2.5.2. Market size of HSV Infection by Clinical Manifestations in the UK
12.2.5.3. Treatment Type & Therapy Based Market Size of HSV Infection
12.2.5.4. Herpes Simplex Virus Infections Market by Emerging Therapies
12.3. Japan: Market Analysis
12.3.1. Market Size of HSV Infection in Japan
12.3.2. Market size of HSV Infection by Clinical Manifestations in Japan
12.3.3. Treatment Type & Therapy Based Market Size of HSV Infection
12.3.4. Herpes Simplex Virus Infections Market by Emerging Therapies
13. Market Drivers of HSV
14. Market Barriers of HSV
15. Appendix
15.1. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer

Request for sample pages: https://www.delveinsight.com/report-store/herpes-simplex-market-insight-epidemiology-and-market-forecast

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.